CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Închisă

1.34 -0.74

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.33

Maxim

1.35

Indicatori cheie
By Trading Economics
Venit	-1.5M -19M
Vânzări	1.7M 1.5M
EPS	-0.06
Marjă de profit	-1,250.946
Angajați	116
EBITDA	-987K -17M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+763.43% upside

Dividende
By Dow Jones
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-173M 454M
Deschiderea anterioară	2.08
Închiderea anterioară	1.34

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 mai 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 mai 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 mai 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 mai 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 mai 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 mai 2026, 22:26 UTC

Achiziții, Fuziuni, Preluări

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 mai 2026, 22:25 UTC

Achiziții, Fuziuni, Preluări

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 mai 2026, 22:25 UTC

Achiziții, Fuziuni, Preluări

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 mai 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 mai 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 mai 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 mai 2026, 22:23 UTC

Achiziții, Fuziuni, Preluări

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 mai 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 mai 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

23 mai 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 21:10 UTC

Câștiguri

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 mai 2026, 19:47 UTC

Câștiguri

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 mai 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 mai 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 mai 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 mai 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 mai 2026, 18:35 UTC

Achiziții, Fuziuni, Preluări

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 mai 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 mai 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

763.43% sus

Prognoză pe 12 luni

Medie 11.57 USD 763.43%

Maxim 22 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.